11/1
08:15 am
kpti
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.